Outcomes in studies regarding older patients with prostate cancer: A systematic review.

Autor: Jochems KFT; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland; Surgery, Leiden University Medical Center, Leiden, the Netherlands., Menges D; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland., Sanchez D; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland., de Glas NA; Oncology, Leiden University Medical Center, Leiden, the Netherlands., Wildiers H; Oncology, University Hospital Leuven, Leuven, Belgium., Eberli D; Urology, University Hospital Zurich, Zurich, Switzerland., Puhan MA; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland., Bastiaannet E; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. Electronic address: esther.bastiaannet@uzh.ch.
Jazyk: angličtina
Zdroj: Journal of geriatric oncology [J Geriatr Oncol] 2024 Jun; Vol. 15 (5), pp. 101763. Date of Electronic Publication: 2024 Apr 04.
DOI: 10.1016/j.jgo.2024.101763
Abstrakt: Introduction: Older patients are often deemed ineligible for clinical research, and many frequently-used endpoints and outcome measures are not as relevant for older patients for younger ones. This systematic review aimed to present an overview of outcomes used in clinical research regarding patients over the age of 65 years with prostate cancer.
Materials and Methods: PubMed and Embase were systematically searched to identify studies on prostate cancer (treatment) in patients aged ≥65 between 2016 and 2023. Data on title, study design, number of participants and age, stage of disease, treatment, and investigated outcomes were synthesized and descriptively analyzed.
Results: Sixty-eight studies were included. Of these most included patients over 65 years, while others used a higher age. Overall, 39 articles (57.3%) reported on survival-related outcomes, 22 (32.4%) reported on progression of disease and 38 (55.9%) used toxicity or adverse events as an outcome measure. Health-related quality of life and functional outcomes were investigated in 29.4%, and cognition in two studies. The most frequently investigated survival-related outcomes were overall and cancer-specific survival (51.3%); however, 38.5% only studied overall survival.
Discussion: The main focus of studies included in this review remains survival and disease progression. There is limited attention for health-related quality of life and functional status, although older patients often prioritize the latter. Future research should incorporate outcome measures tailored to the aged population to improve care for older patients with prostate cancer.
Competing Interests: Declaration of Competing Interest No conflict of interest for all authors.
(Copyright © 2024. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: